QLGN
- Qualigen Therapeutics, Inc.
()
Overview
Company Summary
Qualigen Therapeutics, Inc. (QLGN) is a biotechnology company that specializes in advancing novel technologies to develop innovative and effective therapeutic products. The company primarily focuses on the research, development, and commercialization of treatments for various diseases, including cancer and infectious diseases.
One of Qualigen's notable technologies is FastPack�, a rapid diagnostic platform that enables the quick and accurate measurement of various analytes, such as tumor markers, hormones, and infectious diseases. This platform utilizes immunochromatographic technology, providing results within minutes, making it useful in point-of-care settings.
In addition to its diagnostic tools, Qualigen is also engaged in the development of novel therapeutics. The company has a strong emphasis on utilizing nucleic acid-based therapies to target diseases such as cancer. It has developed proprietary drug candidates, including RAS-F, ALAN, AS1411, and STARS. These candidates aim to treat conditions like colorectal cancer, and the company is actively conducting clinical trials to evaluate their safety and efficacy.
Furthermore, Qualigen has also ventured into the field of COVID-19 testing in response to the ongoing global pandemic. They have developed the FastPack� IP System, which offers rapid, accurate, and easy-to-use COVID-19 antigen testing.
Overall, Qualigen Therapeutics, Inc. is dedicated to advancing medical technologies and therapies to improve patient care and outcomes, with a focus on developing innovative diagnostics and therapeutics across a range of diseases, including cancer and infectious diseases.